Quest Diagnostics Integrates Oncology Tests into OncoEMR, Enhancing Cancer Care

Quest Diagnostics Integrates Oncology Tests into OncoEMR, Enhancing Cancer Care

Sun, July 19, 2026

Quest Diagnostics Integrates Oncology Tests into OncoEMR, Enhancing Cancer Care

In a significant advancement for oncology diagnostics, Quest Diagnostics (NYSE: DGX) has integrated its Haystack MRD® ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers into OncoEMR®, an electronic health record (EHR) system developed by Flatiron Health. This integration, announced on July 8, 2026, positions Quest as the largest clinical reference laboratory to extend oncology test access through OncoEMR’s Molecular Profiling Integration (MPI) feature.

Enhancing Access to Advanced Oncology Testing

The collaboration aims to streamline the ordering and reporting of complex oncology tests, thereby improving the efficiency and accuracy of cancer diagnostics. American Oncology Network (AON) and other community oncology providers are participating in a pilot program to implement this integration. By embedding Quest’s advanced diagnostic services directly into the OncoEMR platform, healthcare providers can more easily access and interpret critical test results, facilitating timely and informed treatment decisions.

Financial Performance and Market Position

Quest Diagnostics has demonstrated robust financial performance in recent quarters. In the first quarter of 2026, the company reported revenues of $2.90 billion, marking a 9.2% increase from the previous year, with 9.0% organic revenue growth. Reported diluted earnings per share (EPS) rose by 15.5% to $2.24, while adjusted diluted EPS increased by 13.1% to $2.50. These strong financial results led Quest to raise its full-year 2026 guidance, now expecting reported diluted EPS between $9.58 and $9.78, and adjusted diluted EPS between $10.63 and $10.83.

As of July 17, 2026, Quest Diagnostics’ stock (DGX) was trading at $210.68, reflecting investor confidence in the company’s strategic initiatives and financial health.

Strategic Collaborations and Technological Advancements

This integration with OncoEMR is part of Quest’s broader strategy to enhance its technological capabilities and expand its service offerings. In September 2025, Quest announced a collaboration with Epic to improve the laboratory testing experience through Project Nova, a multi-year initiative aimed at simplifying and enhancing customer-facing processes. This collaboration involves implementing Epic’s Diagnostic Enterprise system across Quest’s national laboratory operations, further demonstrating Quest’s commitment to leveraging technology to improve healthcare delivery.

Implications for Healthcare Providers and Patients

The integration of Quest’s oncology tests into OncoEMR is expected to have several positive implications:

  • Improved Workflow Efficiency: Healthcare providers can order and receive test results within the same EHR system, reducing administrative burdens and potential errors.
  • Enhanced Diagnostic Accuracy: Access to comprehensive genomic profiling and minimal residual disease testing can lead to more precise diagnoses and personalized treatment plans.
  • Timely Treatment Decisions: Faster access to critical diagnostic information enables clinicians to make informed decisions promptly, potentially improving patient outcomes.

Conclusion

Quest Diagnostics’ integration of its advanced oncology testing services into OncoEMR represents a significant step forward in the realm of cancer diagnostics. By enhancing access to critical diagnostic tools and streamlining workflows, this collaboration has the potential to improve both the efficiency of healthcare delivery and the quality of patient care. As Quest continues to invest in technological advancements and strategic partnerships, it solidifies its position as a leader in the diagnostic information services industry.